A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial

与单独放化疗相比，放化疗后辅助化疗作为局部晚期宫颈癌主要治疗的 III 期试验：OUTBACK 试验

• 批准号: nhmrc : 1044349
• 负责人: A/Pr Kailash Narayan
• 金额: $ 102.73万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/phase-iii-trial-outback-trial/111654
• 关键词: Phase; III; trial; adjuvant; chemotherapy

This international randomized phase III trial will test the value of giving additional chemotherapy treatment to women with locally advanced cervix cancer following standard chemo-radiation treatment. The aim is to improve survival rates for these women, many of whom have a 40% or greater chance of their disease relapsing after treatment. The trial has been designed in Australia, and is open in multiple countries with Australia New Zealand Gynaecological Oncology Group (ANZGOG) as the lead group.

这项国际随机III期试验将测试在标准化放疗后给予局部晚期宫颈癌妇女额外化疗的价值。其目的是提高这些妇女的生存率，其中许多人在治疗后有40%或更高的疾病复发机会。该试验在澳大利亚设计，并在多个国家开放，澳大利亚新西兰妇科肿瘤组（ANZGOG）作为牵头组。